REDWOOD CITY, Calif., Aug. 27, 2015 (GLOBE NEWSWIRE) -- New biomarker data related to OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) Phase 1b/2 PINNACLE clinical trial of tarextumab (Anti-Notch 2/3, OMP-59R5) in small cell lung cancer (SCLC) will be presented by academic collaborator, Anne Chiang M.D., Ph.D., of the Yale School of Medicine, during a mini oral discussion session at the upcoming 16th World Conference on Lung Cancer taking place September 6-9 in Denver, CO. Details for the presentation are provided below.
Wednesday, September 9, 2015
Mini27.08: NOTCH3 Protein Expression and Outcome in Small Cell Lung Cancer (SCLC) and Therapeutic Targeting with Tarextumab (Anti-Notch 2/3)
Lead author: Anne Chiang, M.D., Ph.D., Yale School of Medicine
Session: Mini Oral 27: Biology and Other Issues in SCLC
Location: Colorado Convention Center, Room 605+607
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer product candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immunotherapy product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.
|Media & Investors||Investors|
|OncoMed Pharmaceuticals||Shari Annes|
|Michelle Corral||Annes Associates|
|Senior Director, Investor Relations and Corporate Communicationsfirstname.lastname@example.org|
Source:OncoMed Pharmaceuticals, Inc.